Huaxin Pharmaceutical (Hxzy) Brand Ranking
If you want to improve the ranking of your company brand or wish to avoid appearing here, please contact trading@bossgoo.com.
Huaxin Pharmaceutical (HXZY)

Huaxin Pharmaceutical (HXZY)

Shandong Huaxin Pharmaceutical Group Co., Ltd.
If you want to improve the ranking of your company brand or wish to avoid appearing here, please contact trading@bossgoo.com.
Brand Introduction

Shandong Huaxin Pharmaceutical Group was founded in March 2002 and is headquartered in Heze High-tech Industrial Park. It has 10 dosage forms including glue, large-capacity injection, tablets, granules, capsules, oral solution, all of which are smooth at one time. Passed the new version of GMP certification. After more than ten years of ups and downs, Huaxin Group has completed a beautiful transformation like a phoenix, growing from an unknown small factory to a modern comprehensive pharmaceutical group integrating scientific research and development, pharmaceutical manufacturing, pharmaceutical economy and trade.

In order to achieve leapfrog development of the enterprise, in 2008, Huaxin Group's decision-making level judged the situation and decisively proposed the development strategy of "changing methods, adjusting structure, expanding the main business, and adding new varieties". It successively acquired Jiangsu Huayuan Pharmaceutical Co., Ltd. and Jiangsu Shutaibao Pharmaceutical. Co., Ltd. and Shaanxi Xinghua Pharmaceutical Co., Ltd. successfully transferred the three new national drug varieties such as Pseudo-Ma Namin Capsules, Meiyu Pseudo-Ma Oral Solution, Longxiang Pingpan Capsules, Yizhong Shengxue Capsules to Huaxin Pharmaceutical Group for the realization of The development strategy of "big variety, large quality, large terminal, and large health" has laid a solid foundation.

Since its establishment, Shandong Huaxin Pharmaceutical Group has taken "building a national brand" as its mission, vigorously developed the donkey-hide gelatin industry, increased the market development and expansion of the Huaxin donkey-hide gelatin series products, deepened the target market, and implemented a full-staff marketing strategy; For the basic brand variety, we will work with major chain dealers and retailers to create a chain terminal market of 100 cities and 100,000 households, focus on the development of terminal markets and the construction of channel networks based on provincial regions, and continuously launch the National Food and Health Word Donkey-hide gelatin health care Products and donkey-hide gelatin food; pay attention to the large-scale operation and standardized operation of donkey-hide gelatin series products to realize the operation of the entire industrial chain of donkey-hide gelatin. Up to now, the company's donkey-hide gelatin series products have been sold to 33 provinces, cities, autonomous regions and Hong Kong across the country, and its market share is still expanding.

Huaxin Group has launched a new product group for upper respiratory tract infections - patented products, national three new drugs: Longxiang Pingpan Capsules, Pseudo-Ma Namin Capsules, Meiyu Pseudo-Ma Oral Liquid and other products, which are new varieties cultivated by the company in the past two years. The national marketing strategy is being promoted, and a sales network and channel covering hospitals and community clinics at all levels are gradually built with prefecture-level cities as the center. Clinical terminal products mainly include the new drugs Longxiang Pingpan Capsule, Yizhong Shengxue Capsule, Zidan Huoxue Capsule, Pseudo-Ma Namin Capsule, Meiyu Pseudo-Ma Oral Solution, and are constantly breaking sales records and continuing to increase their market share. , achieve new breakthroughs in the terminal market.

During the 13th Five-Year Plan period, Huaxin Pharmaceutical Group will continue to adjust its product structure, transform and upgrade its enterprises, focus on the main products (druggar, new drugs), implement the development strategies of large varieties, large terminals, and big health, and standardize corporate operations, , establish and improve the modern enterprise system, connect with the capital market, establish and improve the quality control system for the entire process of drug, implement refined management, intelligent manufacturing, and consistently pursue the safety and functional efficacy of drugs to achieve Huaxin's new takeoff.

Recommend Related Products

版权所有 © 宁波全贸信息技术有限公司 浙ICP备12012821号-1 浙B2-20200628

浙公网安备 33020902000078号